• Test Code:
    2045 (now 1240)1240
  • Department:
  • Test Synonyms:
    Familial Adenomatous Polyposis (FAP) sequencingFull Gene(s) Analysis
  • CPT Code(s):
    Contact KDL for billing information
Background:

MUTYH-associated polyposis is an autosomal recessive disorder associated with numerous colorectal polyps and the attenuated familial adenomatous polyposis (AFAP) phenotype. Attenuated familial adenomatous polyposis (AFAP) is similar to familial adenomatous polyposis (FAP), but with fewer polyps (generally less than 100), polyps located more proximally in the colon, as well as a later age of onset by approximately 10 years. Depending on the population studied, small germline mutations in APC account for 70-90% of FAP cases and 16% of AFAP cases while larger deletions and duplications of APC account for approximately 15% of FAP/AFAP cases. Biallelic MUTYH mutations are identified in approximately 20% of FAP and 30% of AFAP patients that have no mutations detected in APC.

Reasons for Referral:

  • Identification of inherited genetic defects in MUTYH in patients with FAP/AFAP characteristics or early onset colon cancer.
  • Confirmation of a suspected diagnosis with a positive family history of early onset colon cancer when a familial mutation is known.
  • Predispositional testing for asymptomatic family members with a positive family history of colorectal cancer.
For detailed information and ordering instructions, please refer to Full Gene Analysis (1240). Genes may be added or removed if clinically indicated.

Methodology:

Specimen Requirements:

Test Performed (Days):

Turn Around Time:

Shipment Sensitivity Requirements:

References:

  1. Lefevre M, et al. Implications of MYH in Colorectal Polyposis. Ann Surg 2006; 244: 874-879.
  2. Aretz S, et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int. J.  Cancer 2006; 119: 807-814.
  3. Aretz S, et al. Large submicroscopic genomic APC deletions are a common cause of typical familial adenomatous polyposis. J Med Genet 2005; 42: 185-192.
  4. Aretz S, et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int. J.  Cancer 2006; 119: 807-814.
  5. Giardiello F, et al. AGA Technical Review on Hereditary Colorectal Cancer and Genetic Testing. Gastroenterology 2001; 121: 198-213.
  6. Lefevre M, et al. Implications of MYH in Colorectal Polyposis. Ann Surg 2006; 244: 874-879.
  7. Nielsen M, et al. Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. Clin Genet 2007; 71: 427-433.

Additional Info:

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More